Market Research Report

A quick peek into the report

MRD Testing Market - Global and Regional Analysis

Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033

Some Faq's

Frequently Asked Questions

Minimal residual disease (MRD) testing is a supplementary approach to detect extremely low levels of blood cancer cells and solid tumors following the treatment of conditions such as acute and chronic leukemia, lymphoma, or multiple myeloma. MRD specifically pertains to the minute population of cancer cells that persist in the body despite achieving complete remission (CR) through chemotherapy or stem cell transplantation.

Synergistic activities and product launches/approvals accounted for the maximum number of key developments, which was more than 50% of the total developments in the global MRD market as of May 2023. Key players such as Adaptive Biotechnologies collaborated on a translational partnership with Takeda to employ its clonoSEQ assay throughout Takeda's range of hematologic malignancy treatments, enabling the measurement of minimal residual disease.  

The global MRD testing market is currently witnessing several developments, primarily aimed at introducing new products and services. Major manufacturers of MRD testing products, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting.

A new entrant can focus on various MRD testing product offerings by established players. The market is fragmented, with established market leaders such as Bio-Rad Laboratories, Inc., ARUP Laboratories, and Guardant Health, Inc., among others, who have had their presence in the market for many years. The new entrants can focus on strategies such as product launches and global expansions for MRD testing.

The following can be termed as some of the USPs of this report:
•    Breakdown of hematological malignancy and solid tumors to its key target detections along with test volume
•    Current market scenario of MRD testing with company share analysis
•    Technology used for MRD Testing and its current trend in the market
•    Legal and regulatory framework, along with the reimbursement scenarios
•    Country-wise and region-wise analysis of the market, including market forecast of segments 
•    Test volume of technologies, target indication, and end user of the MRD testing market

Companies manufacturing and distributing different tests, assays, and panels used for MRD testing in leukemia, lymphoma, and solid tumors, as well as startups looking to enter the MRD market, can buy this report.